Treating COVID-19 with Chloroquine

Journal of Molecular Cell Biology

Volumn 12, Issue 4, 2020, Pages 322-325

  Huang, Mingxing ^a   Tang, Tiantian ^a   Pang, Pengfei ^a   Li, Man ^a   Ma, Ruolan ^c,d   Lu, Jiahui ^a   Shu, Jingxian ^a   You, Yingying ^a   Chen, Binghui ^a   Liang, Jiabi ^a   Hong, Zhongsi ^a   Chen, Huili ^a   Kong, Ling ^b   Qin, Dajiang ^b,c   Pei, Duanqing ^b,c   Xia, Jinyu ^a   Jiang, Shanping ^a   Shan, Hong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Bioland Laboratory   (China)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHLOROQUINE; LOPINAVIR PLUS RITONAVIR; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; RITONAVIR;

ADULT; ARTICLE; CHINA; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; BETACORONAVIRUS; CLINICAL TRIAL; CORONAVIRUS INFECTION; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; PANDEMIC; PHYSIOLOGY; VIRUS PNEUMONIA;

ADULT; BETACORONAVIRUS; CHLOROQUINE; CORONAVIRUS INFECTIONS; DRUG COMBINATIONS; HUMANS; LOPINAVIR; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; RITONAVIR;

EID: 85083247558     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjaa014     Document Type: Article

References (10)

1. Delvecchio, R., Higa, L.M., Pezzuto, P., et al. (2016). Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses 8, 322.
2. Keyaerts, E., Vijgen, L., Maes, P., et al. (2004). In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. 323, 264?268.
3. Kono, M., Tatsumi, K., Imai, A.M., et al. (2008). Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antivir. Res. 77, 150?152.
4. Lu, H., Stratton, C.W., and Tang, Y.W. (2020). Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J. Med. Virol. 92, 401?402.
5. Savarino, A., Di Trani, L., Donatelli, I., et al. (2006). New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 6, 67?69.
6. Wang, M., Cao, R., Zhang, L., et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269?271.
7. World Health Organization. (2020). Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020.World HealthOrganization. https://apps. who.int/iris/handle/10665/330893
8. Zhang, S., Yi, C., Li, C., et al. (2019). Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus. Antivir. Res. 169, 104547.
9. Zhou, P., Yang, X.L., Wang, X.G., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270?273
10. Zhu, N., Zhang, D., Wang, W., et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727?733